Our Partners
NCIMI brings together hospital trusts, industry innovators, charities, patient groups and funders
Funding Partner
NCIMI has been funded by the Industrial Strategy Challenge Fund through Innovate UK, part of UK Research and Innovation.
Our Industry Partners
|
|
|
Alliance Medical are Europe’s leading independent provider of medical imaging services. We combine service excellence and innovative imaging technologies to improve patient care and support NHS and independent sector organisations with their ongoing imaging requirements. |
|
|
|
We use new insights from the behavioural sciences and behavioural economics to develop powerful frameworks that fuel deeper understanding of consumer behaviour and ways to influence it. Working with some of the world’s biggest companies, we are pioneering new BE-inspired approaches and reinvigorating traditional research methods |
|
|
|
Using Artificial Intelligence (AI), deep learning algorithms and the clinical, engineering and business expertise of the Brainomix team, we are bringing our complete stroke imaging decision support solution to hospitals worldwide. |
|
|
|
Advanced solutions for personalised cardiovascular risk prediction |
|
|
|
As a leading global medical technology and life sciences company, we provide a broad portfolio of products, solutions and services used in the diagnosis, treatment and monitoring of patients and in the development and manufacture of biopharmaceuticals. We help improve outcomes for healthcare providers and for therapy innovators around the world. |
|
|
|
We deliver digital technologies that help clinicians to provide better care for patients with liver disease. |
|
|
|
We’re here to turn questions into answers and answers into treatment. Whether you require software for diagnostic imaging or radiation oncology, our team continually strives to advance the field through its new technologies and by responding and listening to the needs of healthcare professionals. |
|
|
|
Optellum was founded so that every lung cancer patient is diagnosed and treated at the earliest possible stage, and cured. We redefine early interception of lung disease, by enabling every clinician, in every hospital, to manage their patients in the optimal way. |
|
|
|
The world’s first outcomes-driven, AI-based ultrasonic diagnostic support solution for coronary artery disease (CAD). |
|
|
|
Plexalis |
|
|
NHS Hospitals
Our consortium includes NHS hospital trusts across the UK, working with patients across socio and economic backgrounds. Working with anonymous patient data enables us to develop our technologies to help future diagnosis and treatment. Our NHS partners are also crucial in introducing new technologies at the heart of patient care.
|
|
|
|
|
Frimley Health NHS Foundation Trust
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Our Charity Partners
Our charity partners provide crucial insight into patient experience, driving our innovations to improve early diagnosis and inform best treatment.
|
|
|
Haemochromatosis UK supports people with Genetic Haemochromatosis, raise public awareness, educate health care professionals and promote much needed research into haemochromatosis. |
|
|
|
National Cancer Research Institute The NCRI works to coordinate research related to cancer, to improve the quality and relevance of the research and to accelerate translation of the research into clinical practice. |
|
|
|
Our vision is a world free from the fear of heart and circulatory diseases. We raise money to research cures and treatments, so we can beat heartbreak forever. |